FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Issues Patient Preference Info Guidance

[ Price : $8.95]

FDA issues a guidance with concepts for sponsors and stakeholders to consider when choosing to collect and submit patient preferen...

FDA Proposing GLP Quality System

[ Price : $8.95]

FDA proposes regulatory changes to implement a Good Laboratory Practice Quality System to help ensure the quality and integrity of...

QS Problems Found at Tosoh Bioscience

[ Price : $8.95]

FDAs Cincinnati District Office warns Tosoh Bioscience about multiple Quality System regulation violations at its Grove City, OH, ...

General Support for Draft PDUFA 6 Letter

[ Price : $8.95]

Stakeholders voice general support for a PDUFA 6 commitment letter circulated by FDA for comments.

FDA Orphan Status for Huntingtons Disease Antibody

[ Price : $8.95]

FDA grants Vaccinex an orphan drug designation for its therapeutic monoclonal antibody VX15, which is currently being investigated...

Guidance on Device Benefit-Risk Decisions

[ Price : $8.95]

FDA posts a final guidance on Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and...

FDA Priority Review for Clovis Ovarian Cancer Therapy

[ Price : $8.95]

FDA accepts for priority review a Clovis Oncology NDA seeking accelerated approval for rucaparib and its use in treating certain a...

Lilly Wants Forteo ANDAs Rejected

[ Price : $8.95]

Lilly asks FDA to reject ANDAs for its Forteo and ultimately treat it as a biological product after revising the regulatory defini...

Latest FDA Warning Letters

[ Price : $8.95]

In its latest batch of Warning Letters, FDA cites Cape Apothecary, College Pharmacy, Frontida BioPharmm, Huzhou Aupower Sanitary C...

Cubist Dificid Petition Approved, Denied

[ Price : $8.95]

FDA approves in part and denies in part a Cubist petition asking that specific actions be required of ANDA and 505(b)(2) NDA appli...